Diarylethylamines (also 1,2-diarylethylamines) are a chemical class of dissociative drugs characterized by an ethylamine backbone bearing two aryl (aromatic ring) substituents — in contrast to the arylcyclohexylamines (such as ketamine and PCP), where the amine is attached to a cyclohexane ring bearing one aryl group. The class includes diphenidine, ephenidine, fluorolintane (2-FPPI), and several related compounds that emerged primarily as research chemicals in the novel psychoactive substances market beginning around 2013.
Diarylethylamines produce dissociative effects broadly similar to ketamine through NMDA receptor antagonism, but with important pharmacological differences — notably the additional interaction with monoamine transporters (DAT, NET), which confers a stimulant character absent from ketamine. The combination of dissociative and stimulant properties, sometimes described as a "dissociative with a push," creates a qualitatively distinct experience from ketamine and carries a different risk profile including greater psychosis potential and cardiovascular stimulation.
The class is primarily known from harm reduction and research chemical contexts — unlike ketamine, which has legitimate clinical applications and an established safety profile, diarylethylamines lack clinical history and have limited toxicological characterization. Community reports are the primary source of practical knowledge about their effects and risks. The class remains relatively niche within the dissociative space, with far fewer users and documented cases than the arylcyclohexylamine class.
Safety at a Glance
High Risk- Understand the Stimulant Component
- Respect the Duration
- Toxicity: NMDA Antagonist Risks Diarylethylamines carry the general risk profile of NMDA receptor antagonists: - Psychological ...
- Overdose risk: Limited specific overdose data is available for Diarylethylamines. In the absence of compound-spe...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Duration
No duration data available.
How It Feels
The diarylethylamine class, including diphenidine, ephenidine, and methoxphenidine, represents a structurally distinct family of NMDA receptor antagonist dissociatives. Their shared experiential signature differs meaningfully from both the ketamine and PCP families.
The general diarylethylamine experience is characterized by a slow onset, typically one to two hours, followed by a progressive, deepening dissociation that unfolds over an extended duration. The dissociation has a characteristically dark, dreamlike quality, with a sense of slipping into a waking dream rather than being cleanly separated from reality. Physical numbness develops gradually, and the visual field often takes on a tunnel-like or darkened quality.
Cognitive effects tend toward abstract, philosophical ideation with a somewhat flat emotional tone. The stimulation level is moderate, sitting between the sedation of ketamine and the mania of PCP. Duration is typically long, six to ten hours, with protracted aftereffects. The class is notable for its tendency to produce amnesia at higher doses and for a general absence of the warmth and euphoria that characterize more popular dissociatives. Physical safety concerns include the long duration, which can make dosing errors particularly consequential.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(4)
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Pain relief— A suppression of negative physical sensations such as aches and pains, ranging from dulled awareness...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
Cognitive & Perceptual Effects
Cognitive(4)
- Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
- Compulsive redosing— An overwhelming, difficult-to-resist urge to continuously take more of a substance in order to maint...
- Mania— Abnormally elevated mood, energy, and activity with impulsive behavior and grandiosity, associated w...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
Pharmacology
NMDA Receptor Antagonism
Like arylcyclohexylamines, diarylethylamines act as open-channel blockers at NMDA glutamate receptors. NMDA receptor blockade in corticolimbic circuits produces the class-defining dissociative, analgesic, and anesthetic effects. The structural difference from arylcyclohexylamines alters receptor binding kinetics — diarylethylamines generally have somewhat different onset and duration profiles.
Monoamine Reuptake Inhibition
The pharmacologically distinguishing feature of diarylethylamines relative to ketamine is substantial monoamine reuptake inhibition:
- DAT (dopamine transporter): Diphenidine and ephenidine inhibit dopamine reuptake, producing a stimulant, reinforcing component absent from ketamine
- NET (norepinephrine transporter): Norepinephrine reuptake inhibition contributes to cardiovascular stimulation (tachycardia, hypertension) and arousal
- SERT (serotonin transporter): Variable depending on compound; some members show modest SERT inhibition
This monoaminergic activity accounts for the subjective stimulant element of diarylethylamine experiences — accelerated thoughts, heightened energy, compulsive redosing urge — and contributes to the greater psychosis potential compared to ketamine.
Sigma Receptors
Several diarylethylamines show sigma-1 receptor affinity, which may contribute to additional visual and perceptual effects.
Pharmacokinetics
Diarylethylamines are typically active at doses of 50–150 mg orally, with a slower onset than ketamine (45–90 minutes for full effects orally) and a longer duration (6–12 hours for diphenidine). The long and somewhat variable duration is an important harm reduction consideration.
Individual Compounds
Diphenidine (1,2-DEP): The most documented class member; approximately equianalgesic to ketamine with more pronounced monoamine activity. Active ~60–150 mg oral. Ephenidine: N-ethyl analog of diphenidine; qualitatively similar pharmacology. Fluorolintane (2-FPPI): Fluorinated derivative; somewhat shorter duration.
Interactions
No documented interactions.
History
Emergence as Research Chemicals
Diarylethylamines are a relatively recent drug class in recreational and research contexts. Diphenidine was first synthesized by Munch and colleagues in 1924, but attracted no pharmacological interest for decades. The compound re-emerged in the early 2010s when it appeared on the UK research chemical market, likely as a response to increasing legal control of arylcyclohexylamines (methoxetamine, 3-MeO-PCP).
UK Scheduling
Diphenidine and ephenidine were placed under UK Temporary Class Drug Order in 2015 and subsequently made Class B controlled substances — among the first diarylethylamines subjected to formal control. The Psychoactive Substances Act 2016 banned any novel psychoactive substance regardless of scheduling.
Harm Reduction Documentation
The primary body of knowledge about diarylethylamine effects comes from harm reduction communities — particularly Bluelight and Erowid forums — where systematic reports compiled subjective effects, dosing ranges, and adverse events beginning around 2013. The Psychonaut Wiki and similar resources synthesized these community reports into structured articles. Formal academic literature on diarylethylamines is sparse, with a handful of pharmacology papers and forensic chemistry reports constituting the scientific record.
Current Status
Diarylethylamines remain controlled in the UK and various other jurisdictions. They continue to circulate in research chemical markets and among users seeking novel dissociative experiences. The class has not achieved the popularity of arylcyclohexylamines partly due to the intimidating duration and higher unpredictability of the experience, and partly due to the availability of other dissociatives.
Harm Reduction
Understand the Stimulant Component
Unlike ketamine, diarylethylamines produce significant sympathomimetic stimulation alongside dissociation. This changes the experience substantially and has harm reduction implications: users may feel physically energized and capable of activity while profoundly cognitively impaired, creating risk of injury. Physical incapacity from a K-hole may not occur, but cognitive incapacity from NMDA antagonism remains.
Respect the Duration
Diphenidine and similar compounds can last 8–12 hours. Clear your schedule entirely. Do not plan to drive, work, or be in demanding social situations for 12+ hours after dosing.
Safe Environment — Especially Important with Stimulant Dissociatives
The combination of dissociation and stimulant energy makes physical safety critical. Users may feel able to walk around or engage with the environment while their judgment and proprioception are severely impaired. Use in a physically safe, padded space. Have a sober companion.
Start with a Low Dose
Potency varies between preparations and the therapeutic window is narrow. Experienced reports suggest the difference between an interesting experience and a frightening, overwhelming one is often small. 50–60 mg is a commonly cited starting point for diphenidine; many experienced users stay below 100 mg.
Avoid Redosing
The stimulant reinforcement of diarylethylamines creates stronger redosing urges than ketamine. Set a firm limit in advance. Redosing typically produces less effect (tolerance develops) but proportionally more toxicity.
Do Not Combine with Stimulants, Cannabis, or Serotonergic Drugs
Cardiovascular risk is compounded by concurrent stimulant use. Cannabis substantially intensifies dissociative effects in unpredictable ways. MAOIs combined with monoamine reuptake inhibitors can cause dangerous hypertensive or serotonergic crises.
Toxicity & Safety
NMDA Antagonist Risks
Diarylethylamines carry the general risk profile of NMDA receptor antagonists:
- Psychological dissociation and psychosis — Particularly at high doses or with frequent use; the monoaminergic component amplifies psychosis risk relative to ketamine
- Cognitive impairment — Heavy or frequent use may cause persistent impairment in working memory, processing speed, and executive function
- Compulsive use — The dopaminergic component creates stronger reinforcement than ketamine, increasing risk of problematic use patterns
Cardiovascular Stimulation
Unlike ketamine, which has relatively modest cardiovascular effects, diarylethylamines produce more pronounced tachycardia and hypertension through monoamine reuptake inhibition. In users with underlying cardiovascular conditions, this represents meaningful risk.
Duration-Related Risks
The 6–12 hour duration of diphenidine and similar compounds creates extended windows of impaired judgment and physical incapacity. Users may be unable to care for themselves for the majority of a day. This increases the risk of falls, accidents, and inability to seek help in adverse situations.
Urinary Tract
Whether diarylethylamines cause bladder toxicity comparable to ketamine cystitis has not been definitively established, but the class's NMDA antagonist mechanism suggests this risk may exist. Users who develop urinary symptoms should stop use immediately.
Limited Toxicological Characterization
Because diarylethylamines lack clinical history and formal toxicology studies in humans, their long-term risk profile is not well characterized. Community data is the primary knowledge base. Novel compounds in this class should be treated with substantial caution.
Overdose Information
Limited specific overdose data is available for Diarylethylamines. In the absence of compound-specific information, general principles apply:
If someone exhibits signs of medical distress after using Diarylethylamines — difficulty breathing, severe confusion, seizures, chest pain, extremely elevated temperature, or loss of consciousness — treat it as a medical emergency. Call emergency services and be forthcoming about what was consumed. Medical professionals follow confidentiality protocols and their priority is saving lives.
Prevention remains the best approach: use the minimum effective dose, avoid combining with other substances, and always have a sober person present who can recognize signs of distress and call for help.
Tolerance
| Full | Unknown |
| Half | Unknown |
| Zero | Unknown |
Legal Status
The legal status of Diarylethylamines varies by jurisdiction and is subject to change. This information is provided for educational purposes and may not reflect the most current legislation.
General patterns: Many psychoactive substances are controlled under national and international drug control frameworks, including the United Nations Single Convention on Narcotic Drugs (1961), the Convention on Psychotropic Substances (1971), and country-specific legislation such as the US Controlled Substances Act, UK Misuse of Drugs Act, and EU Framework Decisions.
Research chemicals and analogues: Novel psychoactive substances may be captured by analogue laws (e.g., the US Federal Analogue Act) or blanket bans on substance classes (e.g., the UK Psychoactive Substances Act 2016), even if the specific compound is not individually scheduled.
Important note: Possessing, distributing, or manufacturing controlled substances carries serious legal consequences in most jurisdictions. Legal status is not a reliable indicator of a substance's safety profile — some highly dangerous substances are legal, while some with favorable safety profiles are strictly controlled.
Users are strongly encouraged to research the specific legal status of Diarylethylamines in their jurisdiction before any involvement with this substance.
Experience Reports (2)
Tips (2)
Keep a usage log for Diarylethylamines including dose, time, effects, and side effects. This helps you identify patterns and prevent problematic escalation.
Always start with a low dose of Diarylethylamines and work your way up. Individual sensitivity varies, and you cannot undo a dose once taken.
See Also
References (2)
- Diarylethylamines - TripSit Factsheet
TripSit factsheet for Diarylethylamines
tripsit - Diarylethylamines - Wikipedia
Wikipedia article on Diarylethylamines
wikipedia